Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience

Cancer Biology and Therapy

Volumn 15, Issue 5, 2014, Pages 504-509

  Solomon, Maria Teresa ^a   Miranda, Nederlay ^a   Jorrín, Eugenia ^a   Chon, Ivonne ^b   Marinello, Jorge Juan ^b   Alert, José ^b   Lorenzo Luaces, Patricia ^c   Crombet, Tania ^c  

^a HOSPITAL UNIVERSITARIO GENERAL CALIXTO GARCÍA   (Cuba)

^b INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Anaplastic astrocytoma; Glioblastoma multiforme; High grade glioma; Monoclonal antibody; Nimotuzumab; Radiotherapy

Indexed keywords

NIMOTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACIDITY; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRITIS; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; BLURRED VISION; BULIMIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG FEVER; DYSPNEA; FEMALE; GLIOBLASTOMA; HEADACHE; HOARSENESS; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; HYPERSOMNIA; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRADIATION; LEUKOPENIA; LIVER FUNCTION TEST; MAINTENANCE DRUG DOSE; MALE; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; PERSONAL EXPERIENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRURITUS; PULMONARY ASPIRATION; RADIATION DOSE; RASH; RHINITIS; SIDE EFFECT; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; URINE INCONTINENCE; VALIDATION STUDY; WEIGHT GAIN; XEROSTOMIA; ASTROCYTOMA; BRAIN NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; YOUNG ADULT;

EID: 84899795339     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28021     Document Type: Article

References (41)

1. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26:239-44; PMID:8387988; http://dx.doi.org/ 10.1016/0360-3016(93)90203-8 (Pubitemid 23156970)
2. Pang BC, Wan WH, Lee CK, Khu KJ, Ng WH. The role of surgery in high-grade glioma-is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 2007; 36:358-63; PMID:17549284 (Pubitemid 47121451)
3. Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-10; PMID:8478956; http://dx.doi.org/10.1093/jnci/85.9.704 (Pubitemid 23133591)
4. Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas-a clinical review of three selected approaches. Pharmacol Ther 2013; 139:341-58; PMID:23694764; http://dx.doi.org/10.1016/j.pharmthera.2013. 05.003
5. Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med 2013; 15:221-30; PMID:23636139
6. Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO, et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 1992; 12:219-27; PMID:1583555; http://dx.doi.org/10.1007/BF00172709
7. Tsao-Wei DD, Hu J, Groshen SG, Chamberlain MC. Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000. J Neurooncol 2012; 110:145-52; PMID:22875707; http://dx.doi.org/10.1007/s11060-012-0949-6
8. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46:4726-31; PMID:3015394 (Pubitemid 16000351)
9. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369-85; PMID:16890793; http://dx.doi.org/10.1053/j. seminoncol.2006.04.003 (Pubitemid 44142736)
10. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 2013; 34:8690-707; PMID:23953842; http://dx.doi.org/10.1016/j.biomaterials.2013. 07.100
11. Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutationpositive lung adenocarcinoma: a review. Onkologie 2013; 36:510-8; PMID:24051929; http://dx.doi.org/10.1159/000354627
12. Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013; 8:83-96; PMID:23645285; http://dx.doi.org/10.1007/s11523-013-0281-x
13. Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs 2013; 73:315-25; PMID:23440867; http://dx.doi.org/10. 1007/s40265-013-0025-3
14. Fernández A, Pérez R, Macías A, Velandia A, Alvárez I, Ramos M, Velozo A. Generation and characterization of anti-EGFR antibodies. Interferon y Biotecnología 1989; 6:289-98
15. Fernández A, Spitzer E, Pérez R, Boehmer F, Eckert K, Zschiesche W, Grosse R. A new monoclonal antibody for detection of the EGF-R in Western Blot and paraffin embedded tissue sections. J Cell Biochem 1992; 49:157-65; PMID:1400622; http://dx.doi.org/10.1002/jcb.240490208
16. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81; PMID:9154469; http://dx.doi.org/10.1016/S1380-2933(97)00065-1 (Pubitemid 27197395)
17. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-75; PMID:12237899; http://dx.doi.org/10.1002/ijc.10647
18. Diaz Miqueli A, Rolff J, Lemm M, Fichtner I, Perez R, Montero E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 2009; 100:950-8; PMID:19293809; http://dx.doi.org/10.1038/sj.bjc.6604943
19. Perez R, Crombet T, de Leon J, Moreno E. A view on EGFR-targeted therapies from the oncogeneaddiction perspective. Front Pharmacol 2013; 4:53; PMID:23637683; http://dx.doi.org/10.3389/fphar.2013.00053
20. Perez R, Moreno E, Garrido G, Crombet T. EGFRtargeting as a biological therapy: understanding nimotuzumab's clinical effects. Cancers (Basel) 2011; 3:2014-31; PMID:24212794; http://dx.doi.org/10.3390/cancers3022014
21. Bode U, Massimino M, Bach F, Zimmermann M, Khuhlaeva E, Westphal M, Fleischhack G. Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther 2012; 12:1649-59; PMID:23043252; http://dx.doi.org/10.1517/147125 98.2012.733367
22. Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005; 10:760-1; PMID:16249358; http://dx.doi.org/10.1634/ theoncologist.10-9-760 (Pubitemid 41567290)
23. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343-9; PMID:20448462; http://dx.doi.org/10.4161/cbt.9.5.10981
24. Caruso C, Carcaterra M, Donato V. Role of radiotherapy for high grade gliomas management. J Neurosurg Sci 2013; 57:163-9; PMID:23676864
25. Arjona D, Bello MJ, Alonso ME, Gonzalez-Gomez P, Lomas J, Aminoso C, Lopez-Marin I, Isla A, De Campos JM, Vaquero J, et al. Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas. Int J Oncol 2004; 25:1489-94; PMID:15492843
26. Camara-Quintana JQ, Nitta RT, Li G. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 2012; 23:237-46, viii; PMID:22440867; http://dx.doi.org/10.1016/j.nec.2012.01.011
27. Tykocinski ES, Grant RA, Kapoor GS, Krejza J, Bohman LE, Gocke TA, Chawla S, Halpern CH, Lopinto J, Melhem ER, et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 2012; 14:613-23; PMID:22492960; http://dx.doi.org/10. 1093/neuonc/nos073
28. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373-82; PMID:21150278; http://dx.doi.org/10.4161/cbt.11.4.14097
29. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López- Requena A, Pupo A, Johansen RF, Sánchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851-9; http://dx.doi.org/10. 1158/0008-5472.CAN-08-4518; PMID:19584289
30. Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 2013; 13:299; PMID:23782513; http://dx.doi.org/10.1186/1471-2407-13-299
31. Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg 2011; 66:10-7; PMID:21485758; http://dx.doi.org/10.1179/ACB.66.1.2062508
32. Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 2009; 9:703-15; PMID:19601750; http://dx.doi.org/10.2174/187152009788680019
33. Maier S, Peltz G, Penrod JR, Sugarman KP. Retrospective evaluation of cetuximab-related adverse events from claims databases-methodological concerns. Ann Oncol 2010; 21:1731-2, author reply 1732-3; PMID:20605932; http://dx.doi.org/10.1093/annonc/mdq327
34. Nie F, Shen J, Tong JL, Xu XT, Zhu MM, Ran ZH. Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. J Dig Dis 2009; 10:247-57; PMID:19906103; http://dx.doi.org/10.1111/j.1751-2980.2009. 00393.x
35. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibodyrelated hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 2012; 11(Suppl 1):S9-19; PMID:21843103; http://dx.doi.org/10.1517/14740338.2011.606213
36. Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc Hematol Agents Med Chem 2010; 8:156-63; PMID:20446909; http://dx.doi.org/10.2174/187152510791698370
37. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol 2013; 69:463-72; PMID:23602600; http://dx.doi.org/10.1016/j. jaad.2013.02.025
38. Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon Outcomes Res 2012; 4:269-75; PMID:23028234
39. Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013; 7:123-35; PMID:23843722; http://dx.doi.org/10.4137/CMO.S8503
40. Gilbert M, Dignam J, Won M, Blumenthal D, Vogelbaum M, Aldape K, Colman H, Chakravarti A, Jeraj R, Armstrong T et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013; (suppl):abstr 1
41. Henriksson R, Bottomley A, Mason W, Saran F, Wick R, Nishikawa R, Cloughesy T, Carpentier A, Hoang- Xuan K, Kavan P et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 2013 (suppl):abstr 2005